Antibody-drug conjugates (ADCs) are transforming targeted therapies. However, their structural complexity makes selecting the right ADC CDMO partner critical to your clinical and commercial success.
Lonza combines deep scientific expertise with fully integrated development and manufacturing capabilities. We support your ADC programs from early-stage development through to clinical and commercial supply.
Streamlining the ADC Value Chain: What You Will Learn
In this on-demand webinar, Lonza experts share how to enable efficient ADC development and manufacturing across the entire value chain.
Watch the session to gain actionable insights into:
- Complex Conjugation Processes: Overcoming technical hurdles in advanced conjugation.
- Scalable Manufacturing Solutions: Strategies for seamless scale-up from lab to commercial volumes.
- Regulatory Considerations: Navigating compliance pathways to advance your ADCs with confidence.
- Risk Reduction: Streamlining timelines to ensure faster progression to the clinic and market.
Accelerate Your ADC Development Journey
Whether you are initiating a new ADC programme or advancing an existing asset, choosing the right strategy is essential. This session will help you identify the right operational framework—and the right ADC contract manufacturing partner—to meet your technical needs.
